Calcium Magnesium from Dolomite

Calcium (Dolomite):

• Indications and usage
• Dosage and administration
• Dosage forms and strengths
• Contraindications
• Warnings and precautions
• Adverse reactions
• Drug interactions
• Use in specific populations
• Overdosage
• Description
• Clinical pharmacology
• Nonclinical toxicology
• Clinical studies
• How supplied/storage and handling
• Patient counseling information
• Calcium Magnesium from Dolomite (Calcium (Dolomite)) reviews

1 INDICATIONS AND USAGE

Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (ESRD).

- Calcium acetate is a phosphate binder indicated for the reduction of serum phosphorus in patients with end stage renal disease. (1)

2 DOSAGE AND ADMINISTRATION

The recommended initial dose of Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate for the adult dialysis patient is 2 capsules with each meal. Increase the dose gradually to lower serum phosphorus levels to the target range, as long as hypercalcemia does not develop. Most patients require 3 to 4 capsules with each meal.

- Starting dose is 2 capsules with each meal. (2)

- Titrate the dose every 2 to 3 weeks until acceptable serum phosphorus level is reached. Most patients require 3 to 4 capsules with each meal. (2)

3 DOSAGE FORMS AND STRENGTHS

Capsule: 667 mg Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate capsule.

- Capsule: 667 mg Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate capsule. (3)

4 CONTRAINDICATIONS

Patients with hypercalcemia.

- Hypercalcemia. (4)

5 WARNINGS AND PRECAUTIONS

- Treat mild hypercalcemia by reducing or interrupting Calcium Magnesium from Dolomite ) acetate and Vitamin D. Severe hypercalcemia may require hemodialysis and discontinuation of Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate. (5.1)

- Hypercalcemia may aggravate digitalis toxicity. (5.2)

5.1 Hypercalcemia

Patients with end stage renal disease may develop hypercalcemia when treated with Calcium Magnesium from Dolomite (Calcium (Dolomite)), including Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate. Avoid the use of Calcium Magnesium from Dolomite (Calcium (Dolomite)) supplements, including Calcium Magnesium from Dolomite (Calcium (Dolomite)) based nonprescription antacids, concurrently with Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate.

An overdose of Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate may lead to progressive hypercalcemia, which may require emergency measures. Therefore, early in the treatment phase during the dosage adjustment period, monitor serum Calcium Magnesium from Dolomite (Calcium (Dolomite)) levels twice weekly. Should hypercalcemia develop, reduce the Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate dosage, or discontinue the treatment, depending on the severity of hypercalcemia

More severe hypercalcemia (Ca >12 mg/dL) is associated with confusion, delirium, stupor and coma. Severe hypercalcemia can be treated by acute hemodialysis and discontinuing Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate therapy.

Mild hypercalcemia (10.5 to 11.9 mg/dL) may be asymptomatic or manifest as constipation, anorexia, nausea, and vomiting. Mild hypercalcemia is usually controlled by reducing the Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate dose or temporarily discontinuing therapy. Decreasing or discontinuing Vitamin D therapy is recommended as well.

Chronic hypercalcemia may lead to vascular calcification and other soft-tissue calcification. Radiographic evaluation of suspected anatomical regions may be helpful in early detection of soft tissue calcification. The long term effect of Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate on the progression of vascular or soft tissue calcification has not been determined.

Hypercalcemia (>11 mg/dL) was reported in 16% of patients in a 3 month study of solid dose formulation of Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate; all cases resolved upon lowering the dose or discontinuing treatment.

Maintain the serum calcium-phosphorus (Ca x P) product below 55 mg²/dL².

5.2 Concomitant Use with Medications

Hypercalcemia may aggravate digitalis toxicity.

6 ADVERSE REACTIONS

Hypercalcemia is discussed elsewhere [see Warnings and Precautions ].

- The most common (>10%) adverse reactions are hypercalcemia, nausea and vomiting. (6.1)

- In clinical studies, patients have occasionally experienced nausea during Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate therapy. (6)

To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-800-962-8364 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

6.1 Clinical Trial Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In clinical studies, Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate has been generally well tolerated.

Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate was studied in a 3 month, open-label, non-randomized study of 98 enrolled ESRD hemodialysis patients and an alternate liquid formulation of Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate was studied in a two week double-blind, placebo-controlled, cross-over study with 69 enrolled ESRD hemodialysis patients. Adverse reactions (>2% on treatment) from these trials are presented in Table 1.

Mild hypercalcemia may be asymptomatic or manifest itself as constipation, anorexia, nausea, and vomiting. More severe hypercalcemia is associated with confusion, delirium, stupor, and coma. Decreasing dialysate Calcium Magnesium from Dolomite (Calcium (Dolomite)) concentration could reduce the incidence and severity of Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate-induced hypercalcemia. Isolated cases pruritus have been reported, which may represent allergic reactions.

6.2 Postmarketing Experience

Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency or to establish a causal relationship to drug exposure.

The following additional adverse reactions have been identified during post-approval of Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate: dizziness, edema, and weakness.

7 DRUG INTERACTIONS

The drug interaction of Calcium Magnesium from Dolomite ) acetate is characterized by the potential of Calcium Magnesium from Dolomite (Calcium (Dolomite)) to bind to drugs with anionic functions (e.g., carboxyl, and hydroxyl groups). Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate may decrease the bioavailability of tetracyclines or fluoroquinolones via this mechanism.

There are no empirical data on avoiding drug interactions between Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate and most concomitant drugs. When administering an oral medication with Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy, administer the drug one hour before or three hours after Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate. Monitor blood levels of the concomitant drugs that have a narrow therapeutic range. Patients taking anti-arrhythmic medications for the control of arrhythmias and anti-seizure medications for the control of seizure disorders were excluded from the clinical trials with all forms of Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate.

- Calcium acetate may decrease the bioavailability of tetracyclines or fluoroquinolones. (7)

- When clinically significant drug interactions are expected, administer the drug at least one hour before or at least three hours after Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate or consider monitoring blood levels of the drug. (7)

7.1 Ciprofloxacin

In a study of 15 healthy subjects, a co-administered single dose of 4 Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate tablets, approximately 2.7g, decreased the bioavailability of ciprofloxacin by approximately 50%.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category C:

Calcium Magnesium from Dolomite ) acetate capsules contains Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate. Animal reproduction studies have not been conducted with Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate, and there are no adequate and well controlled studies of Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate use in pregnant women. Patients with end stage renal disease may develop hypercalcemia with Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate treatment [see Warnings and Precautions (5.1 ) ]. Maintenance of normal serum Calcium Magnesium from Dolomite (Calcium (Dolomite)) levels is important for maternal and fetal well being. Hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate treatment, as recommended, is not expected to harm a fetus if maternal Calcium Magnesium from Dolomite (Calcium (Dolomite)) levels are properly monitored during and following treatment.

8.2 Labor and Delivery

The effects of Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate on labor and delivery are unknown.

8.3 Nursing Mothers

Calcium Magnesium from Dolomite ) Acetate Capsules contains Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate and is excreted in human milk. Human milk feeding by a mother receiving Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate is not expected to harm an infant, provided maternal serum Calcium Magnesium from Dolomite (Calcium (Dolomite)) levels are appropriately monitored.

8.4 Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

8.5 Geriatric Use

Clinical studies of Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

10 OVERDOSAGE

Administration of Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate in excess of the appropriate daily dosage may result in hypercalcemia [see Warnings and Precautions (5.1)].

11 DESCRIPTION

Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate acts as a phosphate binder. Its chemical name is Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate. Its molecular formula is C₄H₆CaO₄, and its molecular weight is 158.17. Its structural formula is:

Each white opaque/blue opaque capsule contains 667 mg of Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate USP (anhydrous; Ca(CH₃COO)₂; MW=158.17 grams) equal to 169 mg (8.45 mEq) Calcium Magnesium from Dolomite (Calcium (Dolomite)), polyethylene glycol 8000 and magnesium stearate. Each capsule shell contains: black monogramming ink, FD&C Blue #1, FD&C Red #3, gelatin and titanium dioxide. The black monogramming ink contains: ammonium hydroxide, iron oxide black, isopropyl alcohol, n-butyl alcohol, propylene glycol and shellac glaze.

Calcium Magnesium from Dolomite (Calcium (Dolomite)) Acetate Capsules are administered orally for the control of hyperphosphatemia in end-stage renal failure.

Chemical Structure

12 CLINICAL PHARMACOLOGY

Patients with ESRD retain phosphorus and can develop hyperphosphatemia. High serum phosphorus can precipitate serum Calcium Magnesium from Dolomite ) resulting in ectopic calcification. Hyperphosphatemia also plays a role in the development of secondary hyperparathyroidism in patients with ESRD.

12.1 Mechanism of Action

Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate, when taken with meals, combines with dietary phosphate to form an insoluble Calcium Magnesium from Dolomite (Calcium (Dolomite)) phosphate complex, which is excreted in the feces, resulting in decreased serum phosphorus concentration.

12.2 Pharmacodynamics

Orally administered Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate from pharmaceutical dosage forms is systemically absorbed up to approximately 40% under fasting conditions and up to approximately 30% under nonfasting conditions. This range represents data from both healthy subjects and renal dialysis patients under various conditions.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

No carcinogenicity, mutagenicity, or fertility studies have been conducted with Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate.

14 CLINICAL STUDIES

Effectiveness of Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate in decreasing serum phosphorus has been demonstrated in two studies of the Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate solid oral dosage form.

Ninety-one patients with end-stage renal disease who were undergoing hemodialysis and were hyperphosphatemic (serum phosphorus >5.5 mg/dL) following a 1 week phosphate binder washout period contributed efficacy data to an open-label, non-randomized study.

The patients received Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate 667 mg tablets at each meal for a period of 12 weeks. The initial starting dose was 2 tablets per meal for 3 meals a day, and the dose was adjusted as necessary to control serum phosphorus levels. The average final dose after 12 weeks of treatment was 3.4 tablets per meal. Although there was a decrease in serum phosphorus, in the absence of a control group the true magnitude of effect is uncertain.

The data presented in Table 2 demonstrate the efficacy of Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate in the treatment of hyperphosphatemia in end-stage renal disease patients. The effects on serum Calcium Magnesium from Dolomite (Calcium (Dolomite)) levels are also presented.

There was a 30% decrease in serum phosphorus levels during the 12 week study period (p<0.01). Two-thirds of the decline occurred in the first month of the study. Serum Calcium Magnesium from Dolomite (Calcium (Dolomite)) increased 9% during the study mostly in the first month of the study.

Treatment with the phosphate binder was discontinued for patients from the open-label study, and those patients whose serum phosphorus exceeded 5.5 mg/dL were eligible for entry into a double-blind, placebo-controlled, cross-over study. Patients were randomized to receive Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate or placebo, and each continued to receive the same number of tablets as had been individually established during the previous study. Following 2 weeks of treatment, patients switched to the alternative therapy for an additional 2 weeks.

The phosphate binding effect of Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate is shown in the Table 3.

Overall, 2 weeks of treatment with Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate statistically significantly (p<0.01) decreased serum phosphorus by a mean of 19% and increased serum Calcium Magnesium from Dolomite (Calcium (Dolomite)) by a statistically significant (p<0.01) but clinically unimportant mean of 7%.

16 HOW SUPPLIED/STORAGE AND HANDLING

Calcium Magnesium from Dolomite (Calcium (Dolomite)) Acetate Capsules

667 mg capsule is supplied as a white opaque/blue opaque capsule, imprinted with “54 215” on the cap and body.

NDC 0615-2303-39: Blistercards of 30 Capsules

NDC 0615-2303-30: Unit-dose Boxes of 30 Capsules

STORAGE

Store at 20° to 25°C (68° to 77°F).

17 PATIENT COUNSELING INFORMATION

Inform patients to take Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate capsules with meals, adhere to their prescribed diets, and avoid the use of Calcium Magnesium from Dolomite (Calcium (Dolomite)) supplements including nonprescription antacids. Inform the patients about the symptoms of hypercalcemia [see Warnings and Precautions (5.1) and Adverse Reactions (6.1) ].

Advise patients who are taking an oral medication where reduction in the bioavailability of that medication would have clinically significant effect on its safety or efficacy to take the drug one hour before or three hours after Calcium Magnesium from Dolomite (Calcium (Dolomite)) acetate capsules.

Distr. by: West-Ward

Pharmaceuticals Corp.

Eatontown, NJ 07724

10003705/05

Revised April 2016

Magnesium (Dolomite):

• Description
• Clinical pharmacology
• Indications and usage
• Contraindications
• Warnings
• Precautions
• Adverse reactions
• Overdosage
• Dosage and administration
• How supplied
• References
• Calcium Magnesium from Dolomite (Magnesium (Dolomite)) reviews

Calcium Magnesium from Dolomite (Magnesium (Dolomite)) Sulfate

Injection, USP

Ansyr Plastic Syringe

Rx only

Hospira Logo

DESCRIPTION

Calcium Magnesium from Dolomite (Magnesium (Dolomite)) Sulfate Injection, USP is a sterile solution of Calcium Magnesium from Dolomite (Magnesium (Dolomite)) sulfate heptahydrate in Water for Injection, USP administered by the intravenous or intramuscular routes as an electrolyte replenisher or anticonvulsant. Must be diluted before intravenous use. May contain sulfuric acid and/or sodium hydroxide for pH adjustment. The pH is 5.5 to 7.0. The 50% concentration has an osmolarity of 4.06 mOsmol/mL (calc.).

The solution contains no bacteriostat, antimicrobial agent or added buffer (except for pH adjustment) and is intended only for use as a single-dose injection. When smaller doses are required the unused portion should be discarded with the entire unit.

Calcium Magnesium from Dolomite (Magnesium (Dolomite)) Sulfate, USP heptahydrate is chemically designated MgSO₄ - 7H₂O with molecular weight of 246.48 and occurs as colorless crystals or white powder freely soluble in water.

The plastic syringe is molded from a specially formulated polypropylene. Water permeates from inside the container at an extremely slow rate which will have an insignificant effect on solution concentration over the expected shelf life. Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the syringe material.

CLINICAL PHARMACOLOGY

Calcium Magnesium from Dolomite (Magnesium (Dolomite)) (Mg⁺⁺) is an important cofactor for enzymatic reactions and plays an important role in neurochemical transmission and muscular excitability.

As a nutritional adjunct in hyperalimentation, the precise mechanism of action for Calcium Magnesium from Dolomite (Magnesium (Dolomite)) is uncertain. Early symptoms of hypomagnesemia (less than 1.5 mEq/liter) may develop as early as three to four days or within weeks.

Predominant deficiency effects are neurological, e.g., muscle irritability, clonic twitching and tremors. Hypocalcemia and hypokalemia often follow low serum levels of Calcium Magnesium from Dolomite (Magnesium (Dolomite)). While there are large stores of Calcium Magnesium from Dolomite (Magnesium (Dolomite)) present intracellularly and in the bones of adults, these stores often are not mobilized sufficiently to maintain plasma levels. Parenteral Calcium Magnesium from Dolomite (Magnesium (Dolomite)) therapy repairs the plasma deficit and causes deficiency symptoms and signs to cease.

Calcium Magnesium from Dolomite (Magnesium (Dolomite)) prevents or controls convulsions by blocking neuromuscular transmission and decreasing the amount of acetylcholine liberated at the end plate by the motor nerve impulse. Calcium Magnesium from Dolomite (Magnesium (Dolomite)) is said to have a depressant effect on the central nervous system (CNS), but it does not adversely affect the woman, fetus or neonate when used as directed in eclampsia or pre-eclampsia. Normal plasma Calcium Magnesium from Dolomite (Magnesium (Dolomite)) levels range from 1.5 to 2.5 mEq/liter.

As plasma Calcium Magnesium from Dolomite (Magnesium (Dolomite)) rises above 4 mEq/liter, the deep tendon reflexes are first decreased and then disappear as the plasma level approaches 10 mEq/liter. At this level respiratory paralysis may occur. Heart block also may occur at this or lower plasma levels of Calcium Magnesium from Dolomite (Magnesium (Dolomite)). Serum Calcium Magnesium from Dolomite (Magnesium (Dolomite)) concentrations in excess of 12 mEq/L may be fatal.

Calcium Magnesium from Dolomite (Magnesium (Dolomite)) acts peripherally to produce vasodilation. With low doses only flushing and sweating occur, but larger doses cause lowering of blood pressure. The central and peripheral effects of Calcium Magnesium from Dolomite (Magnesium (Dolomite)) poisoning are antagonized to some extent by intravenous administration of calcium.

Pharmacokinetics

With intravenous administration the onset of anticonvulsant action is immediate and lasts about 30 minutes. Following intramuscular administration the onset of action occurs in about one hour and persists for three to four hours. Effective anticonvulsant serum levels range from 2.5 to 7.5 mEq/liter. Calcium Magnesium from Dolomite (Magnesium (Dolomite)) is excreted solely by the kidneys at a rate proportional to the plasma concentration and glomerular filtration.

INDICATIONS AND USAGE

Calcium Magnesium from Dolomite (Magnesium (Dolomite)) Sulfate Injection, USP is suitable for replacement therapy in Calcium Magnesium from Dolomite (Magnesium (Dolomite)) deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. In such cases, the serum Calcium Magnesium from Dolomite (Magnesium (Dolomite)) (Mg⁺⁺) level is usually below the lower limit of normal (1.5 to 2.5 mEq/liter) and the serum calcium (Ca⁺⁺) level is normal (4.3 to 5.3 mEq/liter) or elevated.

In total parenteral nutrition (TPN), Calcium Magnesium from Dolomite (Magnesium (Dolomite)) sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy.

Calcium Magnesium from Dolomite (Magnesium (Dolomite)) Sulfate Injection, USP is also indicated for the prevention and control of seizures (convulsions) in pre-eclampsia and eclampsia, respectively.

CONTRAINDICATIONS

Parenteral administration of the drug is contraindicated in patients with heart block or myocardial damage.

WARNINGS

FETAL HARM: Continuous administration of Calcium Magnesium from Dolomite (Magnesium (Dolomite)) sulfate beyond 5 to 7 days to pregnant women can lead to hypocalcemia and bone abnormalities in the developing fetus. These bone abnormalities include skeletal demineralization and osteopenia. In addition, cases of neonatal fracture have been reported. The shortest duration of treatment that can lead to fetal harm is not known. Calcium Magnesium from Dolomite (Magnesium (Dolomite)) sulfate should be used during pregnancy only if clearly needed. If Calcium Magnesium from Dolomite (Magnesium (Dolomite)) sulfate is given for treatment of preterm labor, the woman should be informed that the efficacy and safety of such use have not been established and that use of Calcium Magnesium from Dolomite (Magnesium (Dolomite)) sulfate beyond 5 to 7 days may cause fetal abnormalities.

ALUMINUM TOXICITY: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

Parenteral use in the presence of renal insufficiency may lead to Calcium Magnesium from Dolomite (Magnesium (Dolomite)) intoxication. Intravenous use in the eclampsia should be reserved for immediate control of life-threatening convulsions.

PRECAUTIONS

General

Administer with caution if flushing and sweating occurs. When barbiturates, narcotics or other hypnotics (or systemic anesthetics) are to be given in conjunction with Calcium Magnesium from Dolomite (Magnesium (Dolomite)), their dosage should be adjusted with caution because of additive CNS depressant effects of Calcium Magnesium from Dolomite (Magnesium (Dolomite)).

Because Calcium Magnesium from Dolomite (Magnesium (Dolomite)) is removed from the body solely by the kidneys, the drug should be used with caution in patients with renal impairment. Urine output should be maintained at a level of 100 mL or more during the four hours preceding each dose. Monitoring serum Calcium Magnesium from Dolomite (Magnesium (Dolomite)) levels and the patient's clinical status is essential to avoid the consequences of overdosage in toxemia. Clinical indications of a safe dosage regimen include the presence of the patellar reflex (knee jerk) and absence of respiratory depression (approximately 16 breaths or more/minute). When repeated doses of the drug are given parenterally, knee jerk reflexes should be tested before each dose and if they are absent, no additional Calcium Magnesium from Dolomite (Magnesium (Dolomite)) should be given until they return. Serum Calcium Magnesium from Dolomite (Magnesium (Dolomite)) levels usually sufficient to control convulsions range from 3 to 6 mg/100 mL (2.5 to 5 mEq/liter). The strength of the deep tendon reflexes begins to diminish when Calcium Magnesium from Dolomite (Magnesium (Dolomite)) levels exceed 4 mEq/liter. Reflexes may be absent at 10 mEq magnesium/liter, where respiratory paralysis is a potential hazard. An injectable calcium salt should be immediately available to counteract the potential hazards of Calcium Magnesium from Dolomite (Magnesium (Dolomite)) intoxication in eclampsia.

50% Calcium Magnesium from Dolomite (Magnesium (Dolomite)) Sulfate Injection, USP must be diluted to a concentration of 20% or less prior to intravenous infusion. Rate of administration should be slow and cautious, to avoid producing hypermagnesemia. The 50% solution also should be diluted to 20% or less for intramuscular injection in infants and children.

Laboratory Tests

Calcium Magnesium from Dolomite (Magnesium (Dolomite)) sulfate injection should not be given unless hypomagnesemia has been confirmed and the serum concentration of Calcium Magnesium from Dolomite (Magnesium (Dolomite)) is monitored. The normal serum level is 1.5 to 2.5 mEq/L.

Drug Interactions

CNS Depressants - When barbiturates, narcotics or other hypnotics (or systemic anesthetics), or other CNS depressants are to be given in conjunction with Calcium Magnesium from Dolomite (Magnesium (Dolomite)), their dosage should be adjusted with caution because of additive CNS depressant effects of Calcium Magnesium from Dolomite (Magnesium (Dolomite)). CNS depression and peripheral transmission defects produced by Calcium Magnesium from Dolomite (Magnesium (Dolomite)) may be antagonized by calcium.

Neuromuscular Blocking Agents - Excessive neuromuscular block has occurred in patients receiving parenteral Calcium Magnesium from Dolomite (Magnesium (Dolomite)) sulfate and a neuromuscular blocking agent; these drugs should be administered concomitantly with caution.

Cardiac Glycosides - Calcium Magnesium from Dolomite (Magnesium (Dolomite)) sulfate should be administered with extreme caution in digitalized patients, because serious changes in cardiac conduction which can result in heart block may occur if administration of calcium is required to treat Calcium Magnesium from Dolomite (Magnesium (Dolomite)) toxicity.

Pregnancy

Teratogenic Effects

Pregnancy Category D (See WARNINGS and PRECAUTIONS )

See WARNINGS and PRECAUTIONS .

Calcium Magnesium from Dolomite (Magnesium (Dolomite)) sulfate can cause fetal abnormalities when administered beyond 5 to 7 days to pregnant women. There are retrospective epidemiological studies and case reports documenting fetal abnormalities such as hypocalcemia, skeletal demineralization, osteopenia and other skeletal abnormalities with continuous maternal administration of Calcium Magnesium from Dolomite (Magnesium (Dolomite)) sulfate for more than 5 to 7 days.^1-10 Calcium Magnesium from Dolomite (Magnesium (Dolomite)) sulfate injection should be used during pregnancy only if clearly needed. If this drug is used during pregnancy, the woman should be apprised of the potential harm to the fetus.

Nonteratogenic Effects

When administered by continuous intravenous infusion (especially for more than 24 hours preceding delivery) to control convulsions in a toxemic woman, the newborn may show signs of Calcium Magnesium from Dolomite (Magnesium (Dolomite)) toxicity, including neuromuscular or respiratory depression (See OVERDOSAGE ).

Labor and Delivery

Continuous administration of Calcium Magnesium from Dolomite (Magnesium (Dolomite)) sulfate is an unapproved treatment for preterm labor. The safety and efficacy of such use have not been established. The administration of Calcium Magnesium from Dolomite (Magnesium (Dolomite)) sulfate outside of its approved indication in pregnant women should be by trained obstetrical personnel in a hospital setting with appropriate obstetrical care facilities.

Nursing Mothers

Since Calcium Magnesium from Dolomite (Magnesium (Dolomite)) is distributed into milk during parenteral Calcium Magnesium from Dolomite (Magnesium (Dolomite)) sulfate administration, the drug should be used with caution in nursing women.

Geriatrics

Geriatric patients often require reduced dosage because of impaired renal function. In patients with severe impairment, dosage should not exceed 20 grams in 48 hours. Serum Calcium Magnesium from Dolomite (Magnesium (Dolomite)) should be monitored in such patients.

ADVERSE REACTIONS

The adverse effects of parenterally administered Calcium Magnesium from Dolomite (Magnesium (Dolomite)) usually are the result of Calcium Magnesium from Dolomite (Magnesium (Dolomite)) intoxication. These include flushing, sweating, hypotension, depressed reflexes, flaccid paralysis, hypothermia, circulatory collapse, cardiac and central nervous system depression proceeding to respiratory paralysis. Hypocalcemia with signs of tetany secondary to Calcium Magnesium from Dolomite (Magnesium (Dolomite)) sulfate therapy for eclampsia has been reported.

OVERDOSAGE

Calcium Magnesium from Dolomite (Magnesium (Dolomite)) intoxication is manifested by a sharp drop in blood pressure and respiratory paralysis. Disappearance of the patellar reflex is a useful clinical sign to detect the onset of Calcium Magnesium from Dolomite (Magnesium (Dolomite)) intoxication. In the event of overdosage, artificial ventilation must be provided until a calcium salt can be injected intravenously to antagonize the effects of Calcium Magnesium from Dolomite (Magnesium (Dolomite)).

For Treatment of Overdose

Artificial respiration is often required. Intravenous calcium, 10 to 20 mL of a 5% solution (diluted if desirable with isotonic sodium chloride for injection) is used to counteract effects of hypermagnesemia. Subcutaneous physostigmine, 0.5 to 1 mg may be helpful.

Hypermagnesemia in the newborn may require resuscitation and assisted ventilation via endotracheal intubation or intermittent positive pressure ventilation as well as intravenous calcium.

DOSAGE AND ADMINISTRATION

Dosage of Calcium Magnesium from Dolomite (Magnesium (Dolomite)) sulfate must be carefully adjusted according to individual requirements and response, and administration of the drug should be discontinued as soon as the desired effect is obtained.

Both intravenous and intramuscular administration are appropriate. Intramuscular administration of the undiluted 50% solution results in therapeutic plasma levels in 60 minutes, whereas intravenous doses will provide a therapeutic level almost immediately. The rate of intravenous injection should generally not exceed 150 mg/minute (1.5 mL of a 10% concentration or its equivalent), except in severe eclampsia with seizures. Continuous maternal administration of Calcium Magnesium from Dolomite (Magnesium (Dolomite)) sulfate in pregnancy beyond 5 to 7 days can cause fetal abnormalities.

Solutions for intravenous infusion must be diluted to a concentration of 20% or less prior to administration. The diluents commonly used are 5% Dextrose Injection, USP and 0.9% Sodium Chloride Injection, USP. Deep intramuscular injection of the undiluted (50%) solution is appropriate for adults, but the solution should be diluted to a 20% or less concentration prior to such injection in children.

In Calcium Magnesium from Dolomite (Magnesium (Dolomite)) Deficiency

In the treatment of mild Calcium Magnesium from Dolomite (Magnesium (Dolomite)) deficiency, the usual adult dose is 1 gram, equivalent to 8.12 mEq of Calcium Magnesium from Dolomite (Magnesium (Dolomite)) (2 mL of the 50% solution) injected intramuscularly every six hours for four doses (equivalent to a total of 32.5 mEq of Calcium Magnesium from Dolomite (Magnesium (Dolomite)) per 24 hours). For severe hypomagnesemia, as much as 250 mg (approximately 2 mEq) per kg of body weight (0.5 mL of the 50% solution) may be given intramuscularly within a period of four hours if necessary. Alternatively, 5 grams, (approximately 40 mEq) can be added to one liter of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP for slow intravenous infusion over a three-hour period. In the treatment of deficiency states, caution must be observed to prevent exceeding the renal excretory capacity.

In Hyperalimentation

In total parenteral nutrition, maintenance requirements for Calcium Magnesium from Dolomite (Magnesium (Dolomite)) are not precisely known. The maintenance dose used in adults ranges from 8 to 24 mEq (1 gram to 3 grams) daily; for infants, the range is 2 to 10 mEq (0.25 gram to 1.25 grams) daily.

In Pre-eclampsia or Eclampsia

In severe pre-eclampsia or eclampsia, the total initial dose is 10 grams to 14 grams of Calcium Magnesium from Dolomite (Magnesium (Dolomite)) sulfate. Intravenously, a dose of 4 grams to 5 grams in 250 mL of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP may be infused. Simultaneously, intramuscular doses of up to 10 grams (5 grams or 10 mL of the undiluted 50% solution in each buttock) are given. Alternatively, the initial intravenous dose of 4 grams may be given by diluting the 50% solution to a 10 or 20% concentration; the diluted fluid (40 mL of a 10% solution or 20 mL of a 20% solution) may then be injected intravenously over a period of three to four minutes. Subsequently, 4 grams to 5 grams (8 to 10 mL of the 50% solution) are injected intramuscularly into alternate buttocks every four hours as needed, depending on the continuing presence of the patellar reflex and adequate respiratory function. Alternatively, after the initial intravenous dose, some clinicians administer 1 gram to 2 grams/hour by constant intravenous infusion. Therapy should continue until paroxysms cease. A serum Calcium Magnesium from Dolomite (Magnesium (Dolomite)) level of 6 mg/100 mL is considered optimal for control of seizures. A total daily (24 hr) dose of 30 grams to 40 grams should not be exceeded. In the presence of severe renal insufficiency, the maximum dosage of Calcium Magnesium from Dolomite (Magnesium (Dolomite)) sulfate is 20 grams/48 hours and frequent serum Calcium Magnesium from Dolomite (Magnesium (Dolomite)) concentrations must be obtained. Continuous use of Calcium Magnesium from Dolomite (Magnesium (Dolomite)) sulfate in pregnancy beyond 5 to 7 days can cause fetal abnormalities.

Other Uses

In counteracting the muscle-stimulating effects of barium poisoning, the usual dose of Calcium Magnesium from Dolomite (Magnesium (Dolomite)) sulfate is 1 gram to 2 grams given intravenously.

For controlling seizures associated with epilepsy, glomerulonephritis or hypothyroidism, the usual adult dose is 1 gram administered intramuscularly or intravenously.

In paroxysmal atrial tachycardia, Calcium Magnesium from Dolomite (Magnesium (Dolomite)) should be used only if simpler measures have failed and there is no evidence of myocardial damage. The usual dose is 3 grams to 4 grams (30 to 40 mL of a 10% solution) administered intravenously over 30 seconds with extreme caution.

For reduction of cerebral edema, 2.5 grams (25 mL of a 10% solution) is given intravenously.

Incompatibilities

Calcium Magnesium from Dolomite (Magnesium (Dolomite)) sulfate in solution may result in a precipitate formation when mixed with solutions containing:

Alcohol (in high Heavy Metals

concentrations) Hydrocortisone sodium

Alkali carbonates and succinate

bicarbonates Phosphates

Alkali hydroxides Polymixin B sulfate

Arsenates Procaine hydrochloride

Barium Salicylates

Calcium Strontium

Clindamycin phosphate Tartrates

The potential incompatibility will often be influenced by the changes in the concentration of reactants and the pH of the solutions.

It has been reported that Calcium Magnesium from Dolomite (Magnesium (Dolomite)) may reduce the antibiotic activity of streptomycin, tetracycline and tobramycin when given together.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

HOW SUPPLIED

Calcium Magnesium from Dolomite (Magnesium (Dolomite)) Sulfate Injection, USP is supplied in single-dose containers as follows:

Do not administer unless solution is clear and container is undamaged. Discard unused portion.

Store at 20 to 25°C (68 to 77°F).

REFERENCES

• Yokoyama K, Takahashi N, Yada Y. Prolonged maternal Calcium Magnesium from Dolomite (Magnesium (Dolomite)) administration and bone metabolism in neonates. Early Hum Dev. 2010;86(3):187-91. Epub 2010 Mar 12.
• Wedig KE, Kogan J, Schorry EK et al. Skeletal demineralization and fractures caused by fetal Calcium Magnesium from Dolomite (Magnesium (Dolomite)) toxicity. J. Perinatol. 2006; 26(6):371-4.
• Nassar AH, Sakhel K, Maarouf H, et al. Adverse maternal and neonatal outcome of prolonged course of Calcium Magnesium from Dolomite (Magnesium (Dolomite)) sulfate tocolysis. Acta Obstet Gynecol Scan. 2006;85(9):1099-103.
• Malaeb SN, Rassi A, Haddad MC. Bone mineralization in newborns whose mothers received Calcium Magnesium from Dolomite (Magnesium (Dolomite)) sulphate for tocolysis of premature labor. Pediatr Radiol. 2004;34(5):384-6. Epub 2004 Feb 18.
• Matsuda Y, Maeda Y, Ito M, et al. Effect of Calcium Magnesium from Dolomite (Magnesium (Dolomite)) sulfate treatment on neonatal bone abnormalities. Gynecol Obstet Invest. 1997;44(2):82-8.
• Schanler RJ, Smith LG, Burns PA. Effects of long-term maternal intravenous Calcium Magnesium from Dolomite (Magnesium (Dolomite)) sulfate therapy on neonatal calcium metabolism and bone mineral content. Gynecol Obstet Invest. 1997;43(4):236-41.
• Santi MD, Henry GW, Douglas GL. Calcium Magnesium from Dolomite (Magnesium (Dolomite)) sulfate treatment of preterm labor as a cause of abnormal neonatal bone mineralization. J Pediatr Orthrop. 1994;14(2):249-53.
• Holcomb WL, Shackelford GD, Petrie RH. Calcium Magnesium from Dolomite (Magnesium (Dolomite)) tocolysis and neonatal bone abnormalities; a controlled study. Obstet Gynecol. 1991; 78(4):611-4.
• Cumming WA, Thomas VJ. Hypermagnesemia: a cause of abnormal metaphyses in the neonate. Am J Roentgenol. 1989; 152(5):1071-2.
• Lamm CL, Norton KL, Murphy RJ. Congenital rickets associated with Calcium Magnesium from Dolomite (Magnesium (Dolomite)) sulfate infusion for tocolysis. J Pediatr. 1988; 113(6):1078-82.
• McGuinness GA, Weinstein MM, Cruikshank DP, et al. Effects of Calcium Magnesium from Dolomite (Magnesium (Dolomite)) sulfate treatment on perinatal calcium metabolism. II. Neonatal responses. Obstet Gynecol. 1980; 56(5): 595-600.
• Riaz M, Porat R, Brodsky NL, et al. The effects of maternal Calcium Magnesium from Dolomite (Magnesium (Dolomite)) sulfate treatment on newborns: a prospective controlled study. J. Perinatol. 1998;18(6 pt 1):449-54.

Hospira, Inc., Lake Forest, IL 60045 USA

LAB-1024-1.0

April 2017

Hospira Logo

50% Calcium Magnesium from Dolomite (Magnesium (Dolomite)) Sulfate 5 g/10 mL (500 mg/mL)

Rx only

NDC 0409-1754-10

10 mL Single-dose syringe

50% Calcium Magnesium from Dolomite (Magnesium (Dolomite)) Sulfate Injection, USP

5 g/10 mL (500 mg/mL) (4 mEq Mg++/mL)

MUST BE DILUTED FOR INTRAVENOUS USE.

For Intravenous or Intramuscular Use. Sterile. 4.06 mOsmol/mL (calc.).

Contains no more than 75 mcg/L of aluminum.

Hospira, Inc., Lake Forest, IL 60045 USA

Hospira

RL-6891